2m 2m 2m 2m 2m 2m 2m
BRIACELL THERAP (BCTX)
NASDAQ
$3.39-$0.12 (-3.39%)
Price as of Nov 13, 2026 12:53 PM EST- $30.7MMarket Cap
- -63.96%1-Year Change
- BiotechnologyIndustry
BRIACELL THERAP (BCTX)
$3.39-$0.12 (-3.39%)
Annual
Quarterly
07/31/2026 | 07/31/2025 | 07/31/2024 | 07/31/2023 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 14,804 -73.79% | 56,473 N/A | N/A N/A | N/A N/A | |
Cost of Revenue | 674,437 -24.39% | 892,005 +66.77% | 534,861 +3.38% | 517,398 N/A | |
Gross Profit | -659,633 -21.05% | -835,532 +56.21% | -534,861 +3.38% | -517,398 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -29.2M +37.45% | -21.3M -21.74% | -27.2M +77.21% | -15.3M +91.19% | |
Depreciation and Amortization Expense | 104,064 +13.91% | 91,356 +33.12% | 68,626 +349.39% | 15,271 -0.007% | |
Total Operating Expenses | 36.1M +32.53% | 27.2M -18.38% | 33.3M +320.01% | 7.9M +9.19% | |
Operating Profit | -36.1M +32.53% | -27.2M -18.38% | -33.3M +43.22% | -23.3M +52.22% | |
Interest Income | 633,766 +428.32% | 119,958 -58.35% | 288,018 -67.68% | 891,213 +551.80% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 633,766 +428.32% | 119,958 -58.35% | 288,018 -67.68% | 891,213 +556.50% | |
Total Nonoperating Income and Expense | 601,461 +425.24% | 114,511 -56.39% | 262,566 -91.16% | 3.0M +303,257.51% | |
Income before Taxes | -36.1M +32.53% | -27.2M -18.38% | -33.3M +43.22% | -23.3M +52.22% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -34.9M +32.66% | -26.3M +449.14% | -4.8M -76.40% | -20.3M -24.35% | |
Net Income from Continuing Operations Applicable to Common | -34.9M +32.66% | -26.3M +449.14% | -4.8M -76.40% | -20.3M -24.35% | |
Basic EPS and Net Income | -6.97 -88.79% | -62.19 +21,344.83% | -0.29 -77.69% | -1.30 -24.86% | |
Diluted EPS and Net Income | -6.97 -88.79% | -62.19 +21,344.83% | -0.29 -77.69% | -1.30 -24.86% | |
Basic Weighted Average Shares | 5.0M +1,084.29% | 423,114 -97.43% | 16.5M +5.35% | 15.6M +0.81% | |
Diluted Weighted Average Shares | 5.0M +1,084.29% | 423,114 -97.43% | 16.5M +5.35% | 15.6M +0.81% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 9.9M -6.11% | 10.5M +1,117.25% | 862,089 -95.94% | 21.3M -48.22% | |
Short-Term Investments | 10.7M +44.98% | 7.4M N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 20.5M +14.97% | 17.9M +1,972.44% | 862,089 -95.94% | 21.3M -48.22% | |
Total Current Assets | 22.0M +10.63% | 19.9M +445.36% | 3.7M -86.44% | 26.9M -36.36% | |
Accumulated Depreciation | 264,046 +65.05% | 159,982 +133.12% | 68,626 N/A | N/A N/A | |
Property and Plant and Equipment and Net | 319,804 +7.74% | 296,819 -23.53% | 388,175 +15,427.00% | 2,500 0.00% | |
Total Long-Term Assets | 1.5M -10.93% | 1.7M -22.33% | 2.2M +931.48% | 215,070 -6.63% | |
Total Assets | 23.6M +8.91% | 21.6M +268.68% | 5.9M -78.38% | 27.2M -36.20% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 8.0M +100.65% | 4.0M -46.68% | 7.5M +314.17% | 1.8M +91.42% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 38,939 -88.47% | 337,672 -69.19% | 1.1M -96.24% | 29.1M -6.92% | |
Total Liabilities | 8.0M +100.65% | 4.0M -46.68% | 7.5M +314.17% | 1.8M +91.42% | |
Retained Earnings | -146.7M +31.23% | -111.8M +30.79% | -85.4M +5.94% | -80.7M +33.64% | |
Total Stockholders Equity | 15.6M -10.24% | 17.3M +745.60% | -2.7M -28.92% | -3.8M -136.57% | |
Total Shares Outstanding | 8.7M +362.23% | 1.9M -89.70% | 18.3M +14.41% | 16.0M +2.99% | |
Cash Flow | |||||
Cash from Operating Activities | -28.7M +1.71% | -28.2M +16.76% | -24.1M +1.61% | -23.7M +90.20% | |
Capital Expenditures | 127,049 N/A | N/A N/A | 456,801 N/A | N/A N/A | |
Cash from Investing Activities | -3.8M -50.23% | -7.6M +1,021.44% | -681,801 N/A | N/A N/A | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 31.8M -30.00% | 45.4M +928.49% | 4.4M +11.75% | 4.0M +205.65% | |
Financials Ratio | |||||
Gross Margin | -4,455.78% +201.16% | -1,479.52% N/A | N/A N/A | N/A N/A | |
Operating Margin | -243,543.89% +405.56% | -48,173.11% N/A | N/A N/A | N/A N/A | |
Return on Assets | -154.34% -19.28% | -191.21% +559.16% | -29.01% -50.18% | -58.22% +9.14% | |
Return on Equity | -212.23% -40.92% | -359.23% -342.24% | 148.29% +123.93% | -619.75% +680.39% | |
Revenue Growth | -73.79% N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 2.76 -44.86% | 5.01 +922.91% | 0.49 -96.73% | 14.96 -66.76% | |
Cash Ratio | 1.23 -53.21% | 2.64 +2,183.98% | 0.12 -99.02% | 11.80 -72.95% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow